ArticleCureus2025
Relapsing Chronic Immune Thrombocytopenia and Thrombosis: A Case Report.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immune thrombocytopenia (ITP) involves an acquired, immune-mediated disorder involving autoantibodies, which target platelet antigens. It may be primary or secondary to an underlying condition. While some may be asymptomatic, others may experience easy bruising, petechiae, purpura, epistaxis, bleeding from the gums, menorrhagia, hematuria, melena, or hematochezia. This is a case of a 21-year-old female who presented to the Emergency Room after experiencing several days of intermittent bruising and menorrhagia. She was found to have a platelet count of 16,000/μL and hemoglobin of 9.7 g/dL with a normal white blood cell count. One of the many clinical challenges for ITP corresponds to the lack of sensitive or specific diagnostic tests. Treatment is strongly advised for those with active bleeding, severe thrombocytopenia or if an invasive procedure is needed. Options for treatment are initially limited to corticosteroids. Alternative treatment options include intravenous immunoglobulin, rituximab, and thrombopoietic receptor agonists. This case was complicated by a recurrence of thrombocytopenia with bleeding despite corticosteroid treatment, followed by thrombosis in the setting of possible antiphospholipid syndrome. The goals for treatment involved not only increasing the platelet count to a level that decreases the risk of bleeding complications but also improving the patient's quality of life. Furthermore, clinical challenges were involved when considering the management of thrombosis in a patient with chronic ITP.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.